Literature DB >> 21105109

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.

Vlad Ratziu1, Stephen Caldwell, Brent A Neuschwander-Tetri.   

Abstract

Insulin sensitizers are attractive candidate therapies for nonalcoholic steatohepatitis mainly because of the strong association between this disease and insulin resistance. This review provides a critical overview of the mechanisms of action, clinical trial results, and safety issues of metformin and glitazones in nonalcoholic steatohepatitis. It also highlights methodological challenges for trial design and proposes endpoints for future proof of principle, registrational, and postmarketing trials.
Copyright © 2010 American Association for the Study of Liver Diseases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21105109     DOI： 10.1002/hep.24042

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


  25 in total

1.  A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.

Authors:  Vlad Ratziu; Muhammad Y Sheikh; Arun J Sanyal; Joseph K Lim; Hari Conjeevaram; Naga Chalasani; Manal Abdelmalek; Anezi Bakken; Christophe Renou; Melissa Palmer; Robert A Levine; B Raj Bhandari; Melanie Cornpropst; Wei Liang; Benjamin King; Elsa Mondou; Franck S Rousseau; John McHutchison; Mario Chojkier
Journal:  Hepatology       Date:  2011-12-14       Impact factor: 17.425

Review 2.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

Review 3.  Pharmacological agents for NASH.

Authors:  Vlad Ratziu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-15       Impact factor: 46.802

Review 4.  Management of nonalcoholic steatohepatitis: Pharmacotherapy.

Authors:  Vlad Ratziu
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-09-25

5.  Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.

Authors:  E Boettcher; G Csako; F Pucino; R Wesley; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2011-11-04       Impact factor: 8.171

6.  Glitazones for human nonalcoholic steatohepatitis.

Authors:  Raluca Pais; Ioana Moraru; Vlad Ratziu
Journal:  Therap Adv Gastroenterol       Date:  2011-09       Impact factor: 4.409

Review 7.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 8.  Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.

Authors:  Juan P Arab; Roberto Candia; Rodrigo Zapata; Cristián Muñoz; Juan P Arancibia; Jaime Poniachik; Alejandro Soza; Francisco Fuster; Javier Brahm; Edgar Sanhueza; Jorge Contreras; M Carolina Cuellar; Marco Arrese; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 9.  The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.

Authors:  Hanford Yau; Kathya Rivera; Romina Lomonaco; Kenneth Cusi
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 10.  Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

Authors:  Stefano Ballestri; Amedeo Lonardo; Stefano Bonapace; Christopher D Byrne; Paola Loria; Giovanni Targher
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.